Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 13/20 | 0.68 |
| ▸ | NQO1 | P15559 | 2/20 | 0.51 |
| ▸ | VKORC1 | Q9BQB6 | 3/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | ALB | P02768 | 1/20 | 0.50 |
| ▸ | PCSK7 | Q16549 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1651720 | 1.00 | CYP2C9 (0.68) | CYP2C9NQO1VKORC1HSD17B10KDM4E | |
| SCHEMBL1479347 | 0.85 | CYP2C9 (0.73) | CYP2C9VKORC1HSD17B10KDM4EALDH1A1 | |
| SCHEMBL20806 | 0.85 | CYP2C9 (0.73) | CYP2C9VKORC1HSD17B10KDM4EALDH1A1 | |
| SCHEMBL136434 | 0.85 | CYP2C9 (0.73) | CYP2C9VKORC1HSD17B10KDM4EALDH1A1 | |
| Phenprocoumon SCHEMBL24500472 | 0.81 | CYP2C9 (1.00) | CYP2C9NQO1VKORC1HSD17B10KDM4E | |
| Phenprocoumon SCHEMBL29392123 | 0.81 | CYP2C9 (1.00) | CYP2C9NQO1VKORC1HSD17B10KDM4E | |
| Phenprocoumon SCHEMBL24500477 | 0.81 | CYP2C9 (1.00) | CYP2C9NQO1VKORC1HSD17B10KDM4E | |
| Phenprocoumon SCHEMBL43031 | 0.81 | CYP2C9 (1.00) | CYP2C9NQO1VKORC1HSD17B10KDM4E | |
| SCHEMBL1649847 | 0.80 | CYP2C9 (0.50) | CYP2C9NQO1HSD17B10KDM4EALDH1A1 | |
| Phosphoric Acid SCHEMBL28278851 | 0.80 | CYP2C9 (0.66) | CYP2C9VKORC1HSD17B10KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 983 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| EP-2988817-B1 | BALLOON CATHETER | INNORA GMBH (DE) | 2022-02-16 | — | — | EP | claimed |
| EP-3721898-B1 | SYNTHETIC PEPTIDES, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND USES THEREOF IN TREATING THROMBOEMBOLISM-RELATED DISEASES | ACADEMIA SINICA (TW) | 2021-11-10 | — | — | EP | claimed |
| US-10806908-B2 | Balloon catheter | INNORA GMBH (DE) | 2020-10-20 | — | — | US | claimed |
| EP-3100728-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING PRASUGREL AND CYCLODEXTRIN DERIVATIVES AND METHODS OF MAKING AND USING THE SAME | CYDEX PHARMACEUTICALS INC (US) | 2019-11-20 | — | — | EP | claimed |
| EP-2782564-B1 | CYSTEAMINE AND/OR CYSTAMINE FOR TREATING ISCHEMIC INJURY | UNIV CALIFORNIA (US) | 2019-01-09 | — | — | EP | claimed |
| EP-2376126-B1 | ANTAGONISTS OF IL-6 TO PREVENT OR TREAT THROMBOSIS | ALDERBIO HOLDINGS LLC (US) | 2017-12-20 | — | — | EP | claimed |
| EP-2391632-B1 | BACTERIOSTATIC CATHETER LOCK CONTAINING GLYCEROL | TELEFLEX MEDICAL INC (US) | 2017-11-15 | — | — | EP | claimed |
| EP-1998825-B1 | ANTIMICROBIAL COMPOSITIONS AND METHODS FOR LOCKING CATHETERS | BECTON DICKINSON CO (US) | 2017-10-18 | — | — | EP | claimed |
| WO-2017140840-A1 | DETERMINATION OF CORRECTED DERIVED FIBRINOGEN RESULTS | ROCHE DIAGNOSTICS GMBH (DE) | 2017-08-24 | — | — | WO | claimed |
| EP-1408949-A2 | GLYCINE BETAINE AND ITS USE AS ANTI-HEMORRHAGIC AGENT | Messadek, Jallal (BE) | 2004-04-21 | — | — | EP | claimed |
| US-20040033223-A1 | Glycine betaine and its use | MESSADEK JALLAL (BE) | 2004-02-19 | — | — | US | claimed |
| US-20030119719-A1 | Use of endothelin conjugates in therapy, new endothelin conjugates, agents that contain the latter, and process for their production | DINKELBORG LUDGER (DE) | 2003-06-26 | — | — | US | claimed |
| WO-2002062322-A2 | GLYCINE BETAINE AND ITS USE AS ANTI-HEMORRHAGIC AGENT | MESSADEK JALLAL (BE) | 2002-08-15 | — | — | WO | claimed |
| US-5985915-A | CARDIOVASCULAR DISORDERS SUCH AS ARRHYTHMIA | SANOFI (FR) | 1999-11-16 | — | — | US | claimed |
| EP-0946205-A2 | USE OF ENDOTHELIN CONJUGATES IN THERAPY, NEW ENDOTHELIN CONJUGATES, SUBSTANCES CONTAINING THEM, AND PROCESSES FOR PRODUCING THEM | SCHERING AKTIENGESELLSCHAFT (DE) | 1999-10-06 | — | — | EP | claimed |
| WO-1998040067-A1 | USE OF BENZOFURAN DERIVATIVES FOR REDUCING DEATH RATE AFTER MYOCARDIAL INFARCTION | SANOFI (FR) | 1998-09-17 | — | — | WO | claimed |
| WO-1998024482-A2 | USE OF ENDOTHELIN CONJUGATES IN THERAPY, NEW ENDOTHELIN CONJUGATES, SUBSTANCES CONTAINING THEM, AND PROCESSES FOR PRODUCING THEM | SCHERING AKTIENGESELLSCHAFT (DE) | 1998-06-11 | — | — | WO | claimed |
| WO-1997034597-A1 | USE OF ANTIARRHYTHMIC COMPOUNDS FOR REDUCING POST-INFARCTION MORTALITY | SANOFI (FR) | 1997-09-25 | — | — | WO | claimed |
| EP-0796617-A1 | Use of antiarhythmic compounds to reduce post-infarct mortality | SANOFI (FR) | 1997-09-24 | — | — | EP | claimed |